Unjha Formulations (BOM:531762) Cyclically Adjusted Revenue per Share: ₹35.62 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531762 Unjha Formulations Ltd BOM:531762
69 GF Score
Price ₹27.50
GF Value ₹22.85
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Unjha Formulations Cyclically Adjusted Revenue per Share?

Unjha Formulations BOM:531762 +0.29% 69 Cyclically Adjusted Revenue per Share is ₹35.62 as of Jun. 2026. GuruFocus rates BOM:531762 with a GF Score™ of 69/100 and a GF Value™ of ₹22.85 (Modestly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Unjha Formulations's adjusted revenue per share for the three months ended in Jun. 2026 was ₹7.378. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹35.62 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Unjha Formulations's average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Unjha Formulations was 8.10% per year. The lowest was 5.30% per year. And the median was 7.20% per year.

As of today (2026-09-01), Unjha Formulations's current stock price is ₹27.50. Unjha Formulations's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹35.62. Unjha Formulations's Cyclically Adjusted PS Ratio of today is 0.77.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Unjha Formulations was 0.97. The lowest was 0.29. And the median was 0.54.


Unjha Formulations  (BOM:531762) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Unjha Formulations's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=27.50/35.62
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Unjha Formulations was 0.97. The lowest was 0.29. And the median was 0.54.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Unjha Formulations Cyclically Adjusted Revenue per Share Related Terms


Unjha Formulations Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Unjha Formulations's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unjha Formulations Cyclically Adjusted Revenue per Share Chart

Unjha Formulations Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.66 30.27 33.21 34.04 35.30

Unjha Formulations Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.51 35.03 35.32 35.30 35.62

BOM:531762 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Unjha Formulations's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unjha Formulations Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Unjha Formulations's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Unjha Formulations's Cyclically Adjusted PS Ratio falls into.


BOM:531762
69GF Score
Unjha Formulations Ltd BOM:531762
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unjha Formulations Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Unjha Formulations's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7.378/167.3573*167.3573
=7.378

Current CPI (Jun. 2026) = 167.3573.

Unjha Formulations Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 3.726 105.961 5.885
201612 7.316 105.196 11.639
201703 6.908 105.196 10.990
201706 6.843 107.109 10.692
201709 6.563 109.021 10.075
201712 5.588 109.404 8.548
201803 5.934 109.786 9.046
201806 7.410 111.317 11.140
201809 6.356 115.142 9.238
201812 4.399 115.142 6.394
201903 7.204 118.202 10.200
201906 6.781 120.880 9.388
201909 6.193 123.175 8.414
201912 3.907 126.235 5.180
202003 5.666 124.705 7.604
202006 5.192 127.000 6.842
202009 4.498 130.118 5.785
202012 5.728 130.889 7.324
202103 6.788 131.771 8.621
202106 8.729 134.084 10.895
202109 4.726 135.847 5.822
202112 7.991 138.161 9.680
202203 9.186 138.822 11.074
202206 5.797 142.347 6.816
202209 10.316 144.661 11.935
202212 7.162 145.763 8.223
202303 6.284 146.865 7.161
202306 8.290 150.280 9.232
202309 10.595 151.492 11.705
202312 12.422 152.924 13.594
202403 9.890 153.035 10.816
202406 8.822 155.789 9.477
202409 8.549 157.882 9.062
202412 8.398 158.323 8.877
202503 5.297 157.552 5.627
202506 8.064 159.755 8.448
202509 9.589 162.289 9.888
202512 9.745 163.281 9.988
202603 7.325 164.272 7.463
202606 7.378 167.357 7.378

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹35.62 mean?
Unjha Formulations (BOM:531762) has a Cyclically Adjusted Revenue per Share of ₹35.62 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Unjha Formulations and its competitors.
Is Unjha Formulations' Cyclically Adjusted Revenue per Share too high?
Unjha Formulations' current Cyclically Adjusted Revenue per Share is ₹35.62. Overall, Unjha Formulations has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Unjha Formulations' Cyclically Adjusted Revenue per Share compare to ZTS?
Unjha Formulations' Cyclically Adjusted Revenue per Share of ₹35.62 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Unjha Formulations and its competitors. Unjha Formulations's current Cyclically Adjusted Revenue per Share is ₹35.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unjha Formulations stock overvalued right now?
Based on GuruFocus' analysis, Unjha Formulations (BOM:531762) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹22.85, compared to a current price of ₹27.50 — trading 20.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹35.62. Unjha Formulations' overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Unjha Formulations (BOM:531762), the current Cyclically Adjusted Revenue per Share is ₹35.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Unjha Formulations (BOM:531762) Overvalued in 2026?

Based on GuruFocus' analysis, Unjha Formulations stock appears to be overvalued. The current stock price of ₹27.50 is trading 20.4% above its estimated GF Value™ of ₹22.85. GuruFocus considers Unjha Formulations to be Modestly Overvalued.

Key valuation signals for BOM:531762:

  • Cyclically Adjusted Revenue per Share: ₹35.62
  • GF Value™: ₹22.85 vs. price of ₹27.50 (20.4% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the BOM:531762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Unjha Formulations Business Description

Address Khali Char Rasta, State Highway, Sidhpur, Khali, Patan, GJ, IND, 384151
Unjha Formulations Ltd is an India-based manufacturer and exporter of Ayurvedic products. The company products include Isabgol powder under the Fibron and Fibron SF name, and Sat-Isabgol and Isabgol Husk. It also offers human and veterinary medicines.
69GF Score

Get the complete analysis for BOM:531762

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹27.50
Price
₹22.85
GF Value